This is a strong fundamental beat that validates the CARVYKTI growth trajectory and the path to profitability. Traders should watch for any commentary on the PRC transfer pricing APA outcome and the pace of CARVYKTI site expansion as key catalysts for sustained upside.
Price Chart
Executive Summary
Legend Biotech reported Q2 2026 results showing a major inflection point: the company achieved its first-ever quarterly net income of $33.2M (vs. -$125.4M loss in Q2 2025), driven by CARVYKTI net trade sales surging 50% YoY to ~$657M. Total revenue grew 52% to $387.5M, and operating income swung to +$57.7M from -$21.9M. The company also raised ~$212M in a June equity offering, ending the period with $965M in cash. The supplemental risk factor regarding PRC transfer pricing negotiations adds a tax overhang.
Key Facts
- First-ever quarterly net income of $33.2M vs. net loss of $125.4M in Q2 2025.
- CARVYKTI net trade sales grew 50% YoY to approximately $657M in Q2 2026.
- Total revenue increased 52% YoY to $387.5M, driven by collaboration revenue of $326.1M and $56M in Janssen milestones.
- Operating income swung to $57.7M from an operating loss of $21.9M in Q2 2025.
- Cash and cash equivalents plus time deposits totaled ~$965M as of June 30, 2026, after a $212M equity offering in June.
- Achieved first clinical proof-of-concept for LB2501 (in vivo CD19/CD20 CAR-T) with 100% ORR at higher dose level.
- Company believes it will achieve company-wide profitability (Adjusted Net Income) in 2026.
- Supplemental risk factor added regarding ongoing PRC transfer pricing negotiations with potential for significant tax liability.
Financial Impact
Q2 2026 net income of $33.2M vs. net loss of $125.4M YoY; total revenue $387.5M (+52% YoY); CARVYKTI net trade sales ~$657M (+50% YoY); operating income $57.7M vs. operating loss $21.9M
Risk Factors
- Ongoing PRC transfer pricing negotiations could result in a material tax liability, as highlighted in the supplemental risk factor.
- Dependence on Janssen partnership for CARVYKTI commercialization; any disruption could impact revenue.
- Competition in the CAR-T space for multiple myeloma (e.g., from Bristol Myers Squibb's Breyanzi) could pressure market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001801198-26-000022 |
| Exhibit: exhibit994-supplementalris.htm | 0001801198-26-000022 |
| Document: a991earningsreleaseq22026.htm | 0001801198-26-000022 |
| Document: 0001801198-26-000022-index-headers.html | 0001801198-26-000022 |
| Document: 0001801198-26-000022-index.html | 0001801198-26-000022 |
| Document: 0001801198-26-000022.txt | 0001801198-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers